Actively Recruiting

Phase 3
Age: 18Years - 95Years
All Genders
NCT05952206

Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy

Led by iVascular S.L.U. · Updated on 2025-05-16

2312

Participants Needed

39

Research Sites

354 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Factorial 2x2, all-comer, multicentre, randomized controlled trial (ratio 1:1:1:1). First, the study will compare (first randomization) the non-inferiority in target lesion failure of angiolite stent versus Xience stent family. Immediately after the first randomization, the study compares (second randomization) the superiority in bleeding Bleeding Academic Research Consortium (BARC) 2, 3, or 5 of abbreviated DAPT versus standard of care. Both primary endpoints will be evaluated at 12 months of follow-up. The study will be open-label for the stent type and the antiplatelet regimen.

CONDITIONS

Official Title

Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy

Who Can Participate

Age: 18Years - 95Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age >18 - < 95 years
  • One or more coronary artery stenosis of 50% or more suitable for stent implantation with vessel diameter at least 2.00 mm
  • Able to provide informed consent and willing to participate in the trial
Not Eligible

You will not qualify if you...

  • Known intolerance to acetylsalicylic acid, P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor), sirolimus, everolimus, or chromium-cobalt
  • Severe hepatic impairment (Child-Pugh stage C)
  • Prior PCI within the last 45 days unrelated to this study
  • Planned non-cardiac surgery during first month after PCI without maintained dual antiplatelet therapy
  • Planned coronary artery bypass graft or other cardiac surgery after index PCI
  • Active major bleeding or major surgery within last 30 days
  • Stroke within 30 days prior to randomization
  • Women of childbearing potential unless permanently sterile or postmenopausal
  • Currently participating in another randomized controlled trial not yet at primary endpoint
  • Life expectancy less than one year due to non-cardiovascular conditions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 39 locations

1

Olv Aalst

Aalst, Belgium

Actively Recruiting

2

IMELDA

Bonheiden, Belgium

Actively Recruiting

3

CHU Marie Curie

Charleroi, Belgium

Actively Recruiting

4

ZOL GENK

Genk, Belgium

Actively Recruiting

5

CHC Montlégia

Liège, Belgium

Actively Recruiting

6

Hospital de La Citadelle

Liège, Belgium

Actively Recruiting

7

Chu Ambroise Pare

Mons, Belgium

Actively Recruiting

8

Az Delta

Roeselare, Belgium

Actively Recruiting

9

Az Turnhout

Turnhout, Belgium

Actively Recruiting

10

Chu Lille

Lille, France

Actively Recruiting

11

Icps Massy

Massy, France

Actively Recruiting

12

Ipcs Quincy

Quincy-sous-Sénart, France

Actively Recruiting

13

Chu Toulouse

Toulouse, France

Actively Recruiting

14

Complejo Hospitalario Universitario A Coruña

A Coruña, Spain

Actively Recruiting

15

Complejo Hospitalario Torrecárdenas

Almería, Spain

Actively Recruiting

16

Hospital Clínic de Barcelona

Barcelona, Spain

Actively Recruiting

17

Hospital de La Santa Creu I Sant Pau

Barcelona, Spain

Actively Recruiting

18

Hospital Germans Trias I Pujol

Barcelona, Spain

Actively Recruiting

19

Hospital Universitario de Bellvitge

Barcelona, Spain

Actively Recruiting

20

Hospital Universitario Vall D'Hebrón

Barcelona, Spain

Actively Recruiting

21

Hospital San Pedro de Alcantara

Cáceres, Spain

Actively Recruiting

22

Hospital Universitario Juan Ramón Jiménez

Huelva, Spain

Actively Recruiting

23

Hospital Universitario Jerez de La Frontera

Jerez de la Frontera, Spain

Actively Recruiting

24

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria, Spain

Actively Recruiting

25

Hospital Universitario de León

León, Spain

Actively Recruiting

26

Hospital Universitario 12 de Octubre

Madrid, Spain

Actively Recruiting

27

Hospital Universitario Puerta de Hierro

Madrid, Spain

Actively Recruiting

28

Hospital Universitario Regional de Málaga

Málaga, Spain

Actively Recruiting

29

Hospital Universitario Virgen de La Victoria

Málaga, Spain

Actively Recruiting

30

Hospital Clínico Universitario Virgen de La Arrixaca

Murcia, Spain

Actively Recruiting

31

Hospital Universitari Son Espases

Palma de Mallorca, Spain

Actively Recruiting

32

Hospital de Navarra

Pamplona, Spain

Actively Recruiting

33

Hospital Universitario Marqués de Valdecilla

Santander, Spain

Actively Recruiting

34

Hospital Clínico Universitario de Santiago

Santiago de Compostela, Spain

Actively Recruiting

35

Hospital Clínico Universitario de Valencia

Valencia, Spain

Actively Recruiting

36

Hospital Universitario Y Politécnico La Fe

Valencia, Spain

Actively Recruiting

37

Hospital Clínico Universitario de Valladolid

Valladolid, Spain

Actively Recruiting

38

Hospital Álvaro Cunqueiro

Vigo, Spain

Actively Recruiting

39

Hospital Universitario Miguel Servet

Zaragoza, Spain

Actively Recruiting

Loading map...

Research Team

S

Sara Pich, PhD

CONTACT

A

Andrea Mancera

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here